Molecular Underpinnings of Heart Failure, Integrative Multi-Omics, and Non-Coding RNA Profiling
Molecular Underpinnings of Heart Failure, Integrative Multi-Omics, and Non-Coding RNA Profiling: the BIOCARDIUM-HF Study
- Heart Failure
- Heart Failure (for Example, Fluid Overload)
At a glance
- Phase
- Phase not stated
- Study type
- Observational
- Sponsor
- University of Zurich
- Enrolment target
- 500
- Started
- 1 February 2025
- Main results due
- 30 November 2030
- Study sites
- 1
- Registry updated
- 25 September 2026
Can you take part?
- No age limit is stated.
- Open to any sex.
- You need the condition being studied — healthy volunteers are not accepted.
These are the headline rules only. Every study has a longer list, and whether you are eligible is decided by the research team at the site — never by this page.
Read the full eligibility criteria
INCLUSION CRITERIA * Female and Male, age ≥18 years at screening. * Diagnosis of Heart Failure according to ESC Heart Failure Guidelines * Ability to understand the requirements of the study and to provide informed consent. * Willingness to undergo follow-up. EXCLUSION CRITERIA Patients will be excluded if they meet any of the following conditions: * Active malignancy or history of cancer with ongoing treatment (e.g., chemotherapy, radiotherapy, immunotherapy). * Autoimmune or systemic inflammatory diseases. * Concomitant infections, including acute systemic infections (e.g., sepsis, pneumonia) or chronic infections with systemic impact (e.g., HIV, hepatitis B/C with elevated transaminases). Other exclusion criteria: * Age\<18 years old * Inability to provide written informed consent
What this study is about
In the sponsor’s own words, from the registry.
The main objective of the study is to achieve a comprehensive phenotyping of patients with heart failure, combining detailed clinical characterization with in-depth molecular profiling. By integrating clinical data with cutting-edge multi-omics techniques (including transcriptomics, epigenomics, and proteomics), this research aims to identify molecular signatures, particularly non-coding RNAs (ncRNAs), that are linked to the onset and progression of HF. Through advanced molecular profiling of biological samples and the analysis of clinical parameters, including advanced imaging, hemodynamic profiling, and biomarker analysis, the study will contribute to the deep phenotyping of HF patients.
The secondary objective aims to uncover potential biomarkers that may serve as predictive indicators of disease progression and identify novel therapeutic targets, offering promising avenues for future treatments in this challenging patient population.
Study sites(1)
University Hospital of Zurich
Zurich, Switzerland
Recruiting
Showing 1 of 1 sites. 1 of the 1 site on this study is recruiting right now — a site can stop enrolling while the study as a whole is still open.
Source: ClinicalTrials.gov record NCT07158086. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.
Not the right study?
Answer three questions and see the studies recruiting near you, in plain language.
Find a study for me